The emergence of SARS-CoV-2 variants harboring mutations in the spike (S) protein has raised concern about potential immune escape. Here, we studied humoral and cellular immune responses to wild type SARS-CoV-2 and the B.1.1.7 and B.1.351 variants of concern in a cohort of 121 BNT162b2 mRNA-vaccinated health care workers (HCW). Twenty-three HCW recovered from mild COVID-19 disease and exhibited a recall response with high levels of SARS-CoV-2-specific functional antibodies and virus-specific T cells after a single vaccination. Specific immune responses were also detected in seronegative HCW after one vaccination, but a second dose was required to reach high levels of functional antibodies and cellular immune responses in all individuals. Vaccination-induced antibodies cross-neutralized the variants B.1.1.7 and B.1.351, but the neutralizing capacity and Fc-mediated functionality against B.1.351 was consistently 2- to 4-fold lower than to the homologous virus. In addition, peripheral blood mononuclear cells were stimulated with peptide pools spanning the mutated S regions of B.1.1.7 and B.1.351 to detect cross-reactivity of SARS-CoV-2-specific T cells with variants. Importantly, we observed no differences in CD4 T-cell activation in response to variant antigens, indicating that the B.1.1.7 and B.1.351 S proteins do not escape T-cell-mediated immunity elicited by the wild type S protein. In conclusion, this study shows that some variants can partially escape humoral immunity induced by SARS-CoV-2 infection or BNT162b2 vaccination, but S-specific CD4 T-cell activation is not affected by the mutations in the B.1.1.7 and B.1.351 variants.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9268159PMC
http://dx.doi.org/10.1126/sciimmunol.abj1750DOI Listing

Publication Analysis

Top Keywords

b117 b1351
20
immune responses
12
sars-cov-2 variants
8
variants concern
8
partially escape
8
escape humoral
8
cellular immune
8
wild type
8
b1351 variants
8
high levels
8

Similar Publications

Article Synopsis
  • Since 2019, COVID-19 has infected hundreds of millions globally, highlighting the importance of developing vaccines in response to variants and vaccine-induced immunity issues.
  • A new recombinant plant-derived vaccine, CoVLP, and a variant-targeted version, CoVLP.B1351, have shown promise in mouse studies to elicit strong immune responses against various COVID-19 variants.
  • Both vaccination approaches generated robust neutralizing antibodies, with a slight advantage for the heterologous prime-boost strategy over the traditional one.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!